HbA1c News and Research

RSS

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Boehringer Ingelheim and Eli Lilly and Company today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor being studied for treatment of patients with Type 2 Diabetes (T2D).

9 Jan 2013

Intensive lifestyle intervention may increase likelihood of partial remission of type 2 diabetes

Among overweight adults, participation in an intensive lifestyle intervention (that included counseling sessions and targets to reduce caloric intake and increase physical activity) was associated with a greater likelihood of partial remission of type 2 diabetes, however the absolute remission rates were modest, according to a study in the December 19 issue of JAMA.

19 Dec 2012

Diabetes tests: an interview with Dr. Danielle Stowasser

Diabetes is a serious condition that causes high levels of glucose (a type of sugar) in the blood. There are three main types of diabetes: type 1 and type 2 diabetes, which are lifelong conditions, and gestational diabetes, which only occurs in women during pregnancy.

3 Dec 2012

Mindful eating reduces weight and blood sugar levels in adults with Type 2 diabetes

Eating mindfully, or consuming food in response to physical cues of hunger and fullness, is just as effective as adhering to nutrition-based guidelines in reducing weight and blood sugar levels in adults with Type 2 diabetes, a new study suggests.

9 Nov 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Results of diabetes management program to be presented at Canadian Cardiovascular Congress

In Canada alone, almost 2 million people are known to be living with diabetes. And around a million more have the disease but are not aware of that fact, and have not been given the tools they need to control their blood sugar and safeguard their health.

29 Oct 2012

HbA1c equally useful across ethnic groups

Currently recommended clinical cutoff points for diabetes diagnosis using glycated hemoglobin should be interpreted similarly in Whites, Blacks, and Hispanics, show findings from a US study.

26 Oct 2012

HbA1c equally useful across ethnic groups

Currently recommended clinical cutoff points for diabetes diagnosis using glycated hemoglobin should be interpreted similarly in Whites, Blacks, and Hispanics, show findings from a US study.

25 Oct 2012

Legume intake reduces heart disease risk in diabetes patients

Diabetes patients who incorporate legumes as part of a low glycemic index diet improve their glycemic control and reduce their risk for coronary heart disease, a study shows.

25 Oct 2012

Canadian Task Force updates diabetes screening guidelines

The Canadian Task Force on Preventive Health Care has updated its recommendations on screening asymptomatic adults for Type 2 diabetes.

19 Oct 2012

Quality of care drops if doctors dictate

Physicians who predominantly dictate patients’ medical notes have worse quality of care than their peers who use structured electronic health record documentation, show study findings.

19 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

12 Oct 2012

HbA1c converter tool launched by NPS

NPS MedicineWise has launched a new online HbA1c converter tool to help people with diabetes understand changes to the way their HbA1c test results are reported in Australia.

10 Oct 2012

Long-term education for patients may futher improve diabetes outcomes

Although there have been significant advances in the provision of diabetes education since 2000, further improvements are still needed, say researchers.

5 Oct 2012

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

MannKind Corporation today announced that it has completed recruiting patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's to-be-marketed next-generation inhaler.

5 Oct 2012

InsuPad device may improve insulin therapy

A novel device is currently under development for aiding insulin analog therapy in diabetes patients, report researchers.

4 Oct 2012

HbA1c News and Research

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Intensive lifestyle intervention may increase likelihood of partial remission of type 2 diabetes

Diabetes tests: an interview with Dr. Danielle Stowasser

Mindful eating reduces weight and blood sugar levels in adults with Type 2 diabetes

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

Results of diabetes management program to be presented at Canadian Cardiovascular Congress

HbA1c equally useful across ethnic groups

HbA1c equally useful across ethnic groups

Legume intake reduces heart disease risk in diabetes patients

Canadian Task Force updates diabetes screening guidelines

Quality of care drops if doctors dictate

One rule for one and one for another with diabetes

HbA1c converter tool launched by NPS

Long-term education for patients may futher improve diabetes outcomes

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

InsuPad device may improve insulin therapy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News